Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2025-12-25 @ 2:38 AM
NCT ID:
NCT00086034
Eligibility Criteria:
Inclusion Criteria:
* ≥ 18 years old
* Refractory or relapsed indolent NHL. Eligible WHO histologies include follicular NHL (Grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and mucosa-associated lymphoid tissue (MALT) types
* Failed ≥ 1 previous regimens, one of which must have contained rituximab as either a single agent or in combination with chemotherapy
* ECOG performance status score either 0 or 1
* Willing and able to provide written informed consent
Exclusion Criteria:
Laboratory values of:
* Platelet count \< 50,000/µL
* AST or ALT \> 2 x the upper limit of normal (ULN)
* Total bilirubin \> 2 x ULN
* Creatinine \> 2.0 mg/dL
and
* Greater than three prior regimens (where a regimen is defined as a treatment for NHL given after disease progression)
* Uncontrolled hypertension
* Known history of porphyria, G6PD deficiency, HIV
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00086034
Study Brief:
Protocol Section:
NCT00086034